Actively Recruiting
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-02-26
50
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
Sponsors
C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor
P
Peking University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.
CONDITIONS
Official Title
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Diagnosed with medullary thyroid carcinoma (MTC) and have a surgical indication based on preliminary evaluation, including newly diagnosed or previously treated tumors
- Expected survival of at least 12 weeks
- No major organ dysfunction including heart, lung, liver, kidney, or other major organs
- Willing and able to understand the study and provide written informed consent or assent
You will not qualify if you...
- History of allergies to imaging agents
- Does not meet sedation requirements for PET-CT scan or has contraindications for PET-CT examination
- Pregnant, breastfeeding, or planning to conceive or father children during the trial
- No surgical indication such as no measurable disease, unresectable disease, significant distant metastasis, or refusal of surgery or 68Ga-TCR-FAPI PET/CT-guided surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China, 100021
Actively Recruiting
Research Team
S
Shaoyan Liu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here